Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis

Inclusion Criteria:

• Diagnosis of cystic fibrosis confirmed

• Age ≥18 years

• 30% <FEV1 <70% predicted

• Presence of bronchial congestion reported by the patient or the investigator

Exclusion Criteria:

• Uncontrolled asthma

• Pneumothorax <6 weeks

• Recent severe hemoptysis <6 weeks

• Patient registered on the transplant list

• Exacerbation within 4 weeks (3 months if hospitalization) before screening

• Cardiovascular disorders, electrocardiogram (ECG) parameters or clinicallysignificant respiratory (non-cystic fibrosis) conditions

• Patients unable to perform measurements of ROF, spirometry, plethysmography.

• Any contraindication to manual or instrumental physiotherapy.

• Pregnancy, breastfeeding.

• Patient under tutorship or curatorship

• No affiliation to the French social security

• Patient using Simeox at home

• Patient under Trikafta for less than 6 weeks.

• Patient using Simeox more than twice a week during physiotherapy sessions, notwanting a washout period of 7 days before inclusion